Publication | Closed Access

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

Mutant Flt3-positive AmlOncologyMedicineCombination TherapyPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyNovel TherapyJak InhibitorsDrug Discovery